Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas (Q84183774)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

title

Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas (English)

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

3 December 2024

1 reference

7

Toshi Menju

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21607772

3 December 2024

author name string

Makoto Sonobe

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

Masashi Kobayashi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

Masashi Ishikawa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

Ryutaro Kikuchi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

Ei Nakayama

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

Tsuyoshi Takahashi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

Kazumasa Takenaka

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

Ryo Miyahara

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

Cheng-Long Huang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

Kenichi Okubo

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

Toru Bando

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

Hiroshi Date

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21607772

3 December 2024

publication date

24 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

full work available at URL

2 February 2020

http://link.springer.com/content/pdf/10.1245/s10434-011-1799-8.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

http://link.springer.com/article/10.1245/s10434-011-1799-8/fulltext.html

3 December 2024

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

http://link.springer.com/content/pdf/10.1245/s10434-011-1799-8

3 December 2024

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Annals of Surgical Oncology

3 December 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

volume

19 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

S347-54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21607772 AND SRC:MED&resulttype=core&format=json

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

2 February 2020

cites work

1

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

3 December 2024

2

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

3 December 2024

3

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Lung cancer: intragenic ERBB2 kinase mutations in tumours

3 December 2024

4

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Uncommon V599E BRAF mutations in Japanese patients with lung cancer

3 December 2024

5

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

High frequency of mutations of the PIK3CA gene in human cancers

3 December 2024

6

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

3 December 2024

7

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

3 December 2024

8

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma

3 December 2024

9

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer

3 December 2024

10

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases

3 December 2024

11

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung

3 December 2024

12

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Clinical relevance of KRAS in human cancers

3 December 2024

13

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer

3 December 2024

14

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer

3 December 2024

15

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

3 December 2024

16

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

3 December 2024

17

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

3 December 2024

18

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

3 December 2024

19

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

3 December 2024

20

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

3 December 2024

21

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

3 December 2024

23

52

2665s

S Rodenhuis

1992

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.

3 December 2024

24

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

3 December 2024

25

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer

3 December 2024

26

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Revisions in the International System for Staging Lung Cancer

3 December 2024

27

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Second primary lung cancer

3 December 2024

29

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

3 December 2024

30

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

3 December 2024

31

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

3 December 2024

32

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

3 December 2024

33

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer

3 December 2024

34

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8

Phosphorylation, But Not Overexpression, of Epidermal Growth Factor Receptor Is Associated With Poor Prognosis of Non-Small Cell Lung Cancer Patients

3 December 2024

35

1 reference

https://api.crossref.org/works/10.1245/S10434-011-1799-8